Lennox-Gastaut Syndrome Across the Continuum: Optimizing Seizure and Non-Seizure Outcomes from Pediatrics to Adulthood

Lennox-Gastaut Syndrome Across the Continuum: Optimizing Seizure and Non-Seizure Outcomes from Pediatrics to Adulthood

Webcast
Clinical Conversations in Action: Expert Panels and Case-Driven Breakout Sessions
earn up to 1.0 ACCME credit
Overview
Learning Objectives
CME Information
Faculty and Disclosures
Instructions

Program Overview

Despite advancements in care, patients with Lennox-Gastaut Syndrome (LGS) continue to experience delayed diagnoses, inconsistent access to emerging therapies, and significant unmet needs related to seizure and non-seizure outcomes. These challenges are compounded by a lack of coordinated, multidisciplinary care and limited caregiver engagement in treatment planning.

To address these critical gaps in care, Lennox-Gastaut Syndrome Across the Continuum: Optimizing Seizure and Non-Seizure Outcomes from Pediatrics to Adulthood delivers a CME-certified, virtual learning experience designed to reflect real-world clinical challenges. This program engages healthcare providers through expert-led discussions and real patient documentary vignettes—focusing on practical, evidence-based strategies to enhance outcomes across the lifespan for individuals living with LGS.

Led by a neurologist, pediatrician, and LGS advocate, this program emphasizes:
  •  Early and accurate seizure identification
  •  Integration of emerging treatments into personalized care plans
  •  Multidisciplinary care coordination and support for family caregivers
  •  Strategies for improving transitions from pediatric to adult care

Target Audience

This activity is designed for neurologists, epileptologists, pediatricians, and allied health professionals involved in the management of patients with Lennox-Gastaut Syndrome (LGS).

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Jazz Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • Summarize the different seizure types in LGS to improve diagnostic accuracy and treatment planning. 
  • Implement strategies to reduce diagnostic delays for LGS, enabling earlier intervention and improved long-term outcomes.
  • Review the mechanisms of action, clinical benefits, and limitations of emerging therapies for LGS, and demonstrate how to integrate them into individualized care plans for optimal patient outcomes. 
  • Apply skills to educate and support caregivers in managing LGS-related challenges, with a focus on behavioral management and cognitive support throughout the care continuum. 

Accredited Provider

This activity is jointly provided by Partners for Advancing Clinical Education and Iridium Continuing Education.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Iridium Continuing Education. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. 

Others involved in the planning of this activity have no relevant financial relationships.

The faculty have the following relevant financial relationships with ineligible companies:

Elaine Wirrell, MD
Professor of Neurology, Chair of Child Neurology, Mayo Clinic

Independent Contractor (Including contracted research): Encoded, Grin pharma, Neurocrine
Kelsey Klaas, MD
Assistant Professor of Pediatric and Adolescent Medicine; Medical Co-Director, Pediatric Pain Rehabilitation Center
Nothing to disclose.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:
  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Attend/view the webinar
  • Complete the posttest with a score of 70% or higher
  • Complete the evaluation
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For additional information about the accreditation of this activity, please visit https://partnersed.com

System Requirements

System requirements
This educational activity is supported by an independent educational grant from Jazz Pharmaceuticals.

Maximum Credit Amount: 1.00

Credit Type: ACCME
Release: 09/26/2025
Expiration: 10/09/2025

This educational activity is supported by an independent educational grant from Jazz Pharmaceuticals.

Maximum Credit Amount: 1.00

Credit Type: ACCME
Release: 09/26/2025
Expiration: 10/09/2025